01 Expansion of Passive Voice Biomarkers for Neurological Disease Monitoring Smartphone-based voice capture is increasingly being used to develop passive digital biomarkers for neurological disease monitoring. Rather than relying only on scheduled clinical assessments, these technologies analyze speech characteristics collected during routine smartphone interactions, enabling more continuous and convenient tracking of disease-related changes.
02 Shift Toward Multimodal Wearable Biomarkers in Clinical Trials Wearable technologies are increasingly being integrated into clinical trials to capture multiple physiological and behavioral measures rather than relying on single biomarkers. Instead of collecting isolated data points, connected devices can simultaneously monitor parameters such as sleep, cardiovascular function, physical activity, and movement, enabling broader assessment of patient health in real-world settings.
01 The digital biomarkers market is sensitive to disruptions because its ecosystem relies on globally sourced wearable devices, sensors, semiconductors, connected hardware, and specialized components. Supply interruptions, manufacturing constraints, logistics delays, and geopolitical events can increase component costs, extend product delivery timelines, and affect the deployment of digital biomarker solutions across clinical research and healthcare settings. The market is demonstrating an elastic recovery pattern, as manufacturers and technology providers gradually restore component availability through supplier diversification, capacity adjustments, inventory optimization, and contingency planning, enabling digital biomarker deployment to recover as supply conditions stabilize.
01 The digital biomarkers market forecasts continued investment activity as pharmaceutical companies, healthcare providers, and technology firms increase spending on remote monitoring, AI-enabled biomarker platforms, wearable technologies, and digital endpoints for clinical trials. In November 2025, Indivi secured USD 18 million in investment to accelerate the discovery of treatment-response biomarkers for neuroscience drug development, with a specific focus on Alzheimer’s disease. The funding will support the advancement of Indivi’s digital biomarker platform, enabling researchers to identify and measure treatment responses using objective, data-driven assessments.
01 Adoption of Remote Patient Monitoring and Demand for Objective Clinical Endpoints Drive Market The growing adoption of remote patient monitoring is driving demand for digital biomarkers by enabling healthcare providers and clinical researchers to continuously collect objective physiological and behavioral data outside traditional clinical settings. Wearable devices, smartphones, and connected sensors can capture measures such as activity, sleep, heart rate, speech, and movement, supporting more frequent assessment of patient health. The US FDA continues to support the use of digital health technologies for remote data collection in drug development, accelerating adoption of digital biomarkers and contributing to market growth.The increasing demand for objective and measurable clinical endpoints is creating opportunities for advanced digital biomarker technologies across clinical trials and disease management. Digital biomarkers can provide longitudinal insights into disease progression, treatment response, and patient behavior, particularly in neurological, cardiovascular, and chronic diseases.
01 High Costs of Wearable Devices and Data Privacy Requirements Restrain Market Expansion Digital biomarker implementation often requires wearable devices, smartphones, sensors, software platforms, data storage, and specialized analytics infrastructure, creating significant upfront and recurring costs for healthcare providers and clinical research organizations. These expenses can limit adoption among smaller healthcare facilities and organizations with constrained technology budgets, particularly in emerging markets.Digital biomarkers rely on continuous collection of sensitive physiological, behavioral, and health-related information, increasing concerns regarding data privacy, cybersecurity, consent, and regulatory compliance. Requirements such as HIPAA in the US and GDPR in Europe can create additional operational and technical requirements for organizations collecting and processing digital biomarker data.
01 Integration of Digital Biomarkers into Decentralized Clinical Trials and Expansion of Precision Medicine Offer Growth Opportunities to Market Players The expansion of decentralized and hybrid clinical trials presents a significant market opportunity for digital biomarker providers. Wearables, smartphones, connected sensors, and remote monitoring platforms enable continuous collection of physiological and behavioral data outside conventional clinical settings, reducing dependence on frequent site visits. For example, Roche’s Floodlight MS app uses smartphone-based digital measures to assess cognitive and motor functions in people with multiple sclerosis, demonstrating how digital biomarkers can support continuous disease monitoring and create opportunities for remote, patient-centered clinical assessment.The expansion of precision medicine presents a significant opportunity for digital biomarker providers by enabling more personalized disease assessment, patient stratification, and treatment monitoring. Digital biomarkers can combine physiological, behavioral, and clinical data collected through wearables, smartphones, and connected sensors to identify individual disease patterns and differences in treatment response. As healthcare moves toward individualized care, demand for validated digital biomarkers that provide continuous and patient-specific insights is expected to increase.
01 Need to Ensure Clinical Validation and Manage Data Standardization Hinder Growth Digital biomarkers can vary based on sensor type, measurement conditions, software algorithms, patient behavior, and data collection protocols. Healthcare providers and pharmaceutical companies therefore require robust evidence demonstrating accuracy, reliability, reproducibility, and clinical relevance before integrating these technologies into routine care or clinical trials.Variations in device specifications, data formats, sampling frequencies, and analytical methods can affect biomarker reliability. Organizations therefore require standardized data protocols, robust analytical frameworks, and quality control processes, increasing technical complexity and operational requirements across the digital biomarker ecosystem.